medigraphic.com
ISSN 1561-3062 (Digital)

2012, Número 1

<< Anterior Siguiente >>

Revista Cubana de Obstetricia y Ginecología 2012; 38 (1)


Un análisis de largo plazo del comportamiento de la cirugía conservadora del cáncer de mama

Hernández DD, Díaz MO, Abreu VMR

Idioma: Español
Referencias bibliográficas: 42
Paginas: 117-133
Archivo PDF: 248.43 Kb.


RESUMEN

Introducción: en los últimos años la cirugía conservadora se ha consolidado como un procedimiento válido en el tratamiento de un determinado grupo de pacientes con cáncer de mama, pues permite conseguir un control local satisfactorio con una menor mutilación, sin modificar la supervivencia ni el índice de metástasis a distancia.
Objetivo: determinar los resultados de la cirugía conservadora del cáncer de mama según variables seleccionadas en el período 1991-2009.
Métodos: se realizó un estudio retropestivo longitudinal a mujeres diagnosticadas y tratadas de cáncer de mama a las que se les realizo cirugía conservadora (n= 77), que cumplieron con los criterios de inclusión y exclusión establecidos. El análisis descriptivo de los datos se realizó mediante distribuciones de frecuencias absolutas y relativas. La estimación de las curvas de supervivencia global y libre de recidivas se realizó mediante el método de Kaplan-Meier.
Resultados: el grupo de edad 40 a 59 años fue el predominante para 67,6 %. Solo el 10,4 % de las pacientes tuvieron antecedentes de primera línea positivos de cáncer de mama. La etapa clínica IIA predominó con un 54,5 %, y el tipo histológico más frecuente, el carcinoma ductal infiltrante para un 84,4 %. La supervivencia global para nuestras pacientes fue de un 95 % a los 5 años, el intervalo libre de recidiva fue de un 87,5%.
Conclusiones: nuestros resultados no difieren de los encontrados en los estudios a nivel mundial.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.

  2. Schopper D, de Wolf C: How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer. 2009;45:1916-23.

  3. Thorat Mangesh A, Rangole Ashvin, Nadkarni Mandar S, Parmar Vani, Badwe Rajendra A. Revision Surgery for Breast Cancer. Cancer. Supplement October 15, 2008;113(8).

  4. Adams C, Grey N, Magrath I, Miller A, Torode J. The World Cancer Declaration: is the world catching up? Lancet Oncol. 2010;11:1018-20.

  5. Pike MC, Spicer DV, Dalimoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cáncer risk. Epidemiol Rev. 1991;15:48-65.

  6. Aziz Z, Iqbal J, Akram M, Anderson BO. Worsened oncologic outcomes for women of lower socio-economic status (SES) treated for locally advanced breast cancer (LABC) in Pakistan. Breast. 2010;19:38-43.

  7. Kerr DJ, Midgley R. Can we treat cancer for a dollar a day? Guidelines for lowincome countries. N Engl J Med. 2010;363:801-03.

  8. Paolo Boffetta, Philippe Autier. Is breast cancer associated with tobacco smoking? BMJ. 2011;342:d1093.

  9. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15:233-43.

  10. Bruzzi P, Negri E, La Vecchia C. Short term increase in risk of breast cancer risk in a large cohort of woman. Am J Epidemiol. 1998;147:636-43.

  11. Pike MC, Krailo MD, Henderson BS, Casagrande JT, Hoel DG. Hormonal risk factors, "breast tissue age", and the age-incidence of breast cancer. Nature. 1983;303:767-70.

  12. Russo J, Tay LK, Russo IK. Differentiation of the mammary gland and susceptibility to carcinogénesis. Breast Cancer Res Treat. 1982;2:5-73.

  13. Rosner B, Colditz G. Extended mathematical model of breast cancer incidence in the Nurses´ Health Study. J Natl Cancer Inst. 1996;88:359-64.

  14. La Vecchia C, Negri E, Boyle P. Reproductive factors and breast cáncer: an overview. Soz Praventivmed. 1989;34:101-7.

  15. Lane-Claypon JE. A further report on cancer of the breast, with special reference to its associated antecedent conditions. London: Ministry of Health; 1926.

  16. Romieu J, Hernández-Ávila M, Lazcano E, López L, Romero-Jaime R. Breast cáncer and lactation history in Mexican women. Am J Epidemiol. 1996;132:17-26.

  17. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;47:1713-27.

  18. Colditz GA, Stampfer MJ, Willett WC. Reproducibility and validity of selfreported menopausal status in a prospective cohort study. Am J Epidemiol. 1987;126:319-25.

  19. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713-27.

  20. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101:48-60.

  21. Xue F, Michels KB: Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr. 2007;86:s823-35.

  22. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem. 2008;114:63-70.

  23. Agnoli C, Berrino F, Abagnato CA, Muti P, Panico S, Crosignani P, et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case-control study. Nutr Metab Cardiovasc Dis; 2009.

  24. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98(19):10869-74.

  25. Adami HO, Hansen J, Jung B, Rimsten A. Characteristics of familial breast cancer in Sweden absence of relation to age and unilateral versus bilateral disease. Cancer. 1981;48:1688.

  26. Masood S, Vass L, Ibarra JA Jr. Breast pathology guideline. implementation in low- and middle-income countries. Cancer. 2008;113 (suppl 8):2297-304.

  27. Del Casar JM, Martin A, Garcia C, Corte MD, Alvarez A, Junquera S, et al. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis. Eur J Obstet Gynecol Reprod Biol. 2008;141(2):147-52.

  28. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet; 2008.

  29. Rozas R, Rivas L, Carayhua D. Cáncer de mama en el Hospital Nacional "Daniel Alcides Carrión-Callao". Aspectos anatomopatológicos y epidemiológicos. Acta Cancerológica. 2002;31:89-92.

  30. Thorat MA, Rangole A, Nadkarni MS, Parmar V, Badwe RA. Revision surgery for breast cancer: single-institution experience. Cancer. 2008;113(suppl 8):2347-52.

  31. Newton M, Bird P. Impact of parallel anesthesia and surgical provider training in sub-Saharan Africa: a model for a resource-poor setting. World J Surg. 2010;34:445-52.

  32. Dick AW, Sorbero MS, Ahrendt GM, Hayman JA, Gold HT, Schiffhauer L, et al. Comparative effectiveness of ductal carcinoma in situ management and the roles of margins and surgeons. J Natl Cancer Inst. 2011;103:92-104.

  33. Sakr RA, Poulet B, Kaufman GJ, Nos C, Clough KB. Clear margins for invasive lobular carcinoma: a surgical challenge. Eur J Surg Oncol. 2011;37:350-6.

  34. Olson TP, Harter J, Munoz A, Mahvi DM, Breslin T. Frozen section analysis for intraoperative margin assessment during breast-conserving surgery results in low rates of re-excision and local recurrence. Ann Surg Oncol. 2007;14:2953-60.

  35. Ribelles N, Torres E, Alba E. Factores pronósticos en cáncer de mama Rev Cancer 2002;16(4):127-37.

  36. Van Nes JG, Putter H, Julien JP, Tubiana-Hulin M, van de Vijver MJ, Bogaerts J, et al. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat. 2009;115:101-13.

  37. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (< 35 years) with operable breast cancer. Ann Oncol. 2010;21:1974-81.

  38. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108-14.

  39. Koscielny S, Tubiana M, Le M. Breast cancer: relationship between the size of the primary tumor and the probability of metastatic dissemination. Br J Cancer. 1984;49:709.

  40. Koscielny S, Le M, Tubiana M. The natural history of human breast cancer: the relationship between involvement of axillary lymph nodes and the initiation of distant metastases. Br J Cancer. 1989;59:775.

  41. Sánchez Varela I. Cirugía Conservadora en Cáncer de Mama [tesis]. La Habana: Facultad Manuel Fajardo; 1997.

  42. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825




2020     |     www.medigraphic.com